Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-ss, and MAPK signaling pathways during breast tumor progression

Breast cancer (BC) as one of the most common causes of human deaths among women, is always considered one of the global health challenges. Despite various advances in diagnostic and therapeutic methods, a significant percentage of BC patients have a poor prognosis due to the lack of therapeutic response. Therefore, investigating the molecular mechanisms involved in BC progression can improve the therapeutic and diagnostic strategies in these patients. Cytokine and growth factor-dependent signaling pathways play a key role during BC progression. In addition to cytokines and growth factors, long non-coding RNAs (lncRNAs) have also important roles in regulation of such signaling pathways. Therefore, in the present review we discussed the role of lncRNAs in regulation of PI3K/AKT, MAPK, and TGF-ss signaling pathways in breast tumor cells. It has been shown that lncRNAs mainly have an oncogenic role through the promotion of these signaling pathways in BC. This review can be an effective step in introducing the lncRNAs inhibition as a probable therapeutic strategy to reduce tumor growth by suppression of PI3K/AKT, MAPK, and TGF-ss signaling pathways in BC patients. In addition, considering the oncogenic role and increased levels of lncRNAs expressions in majority of the breast tumors, lncRNAs can be also considered as the reliable diagnostic markers in BC patients.

Automated summary

Breast cancer is a major global health challenge, and investigating the molecular mechanisms involved in its progression can lead to improved therapeutic and diagnostic strategies. Long non-coding RNAs (lncRNAs) play important roles in regulating cytokine and growth factor-dependent signaling pathways in breast tumor cells. This review discusses the oncogenic role of lncRNAs in promoting PI3K/AKT, MAPK, and TGF-β signaling pathways in breast cancer and suggests lncRNA inhibition as a potential therapeutic strategy to reduce tumor growth and as reliable diagnostic markers in breast cancer patients.